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PolyepitopeWe have previously demonstrated that the potent immunogenicity of hepatitis B surface antigen (HBsAg)
may be exploited to deliver foreign antigens for cytotoxic T-lymphocyte (CTL) induction. Here we
demonstrate that a single low-dose immunization with rHBsAg DNA is sufﬁcient to prime for CTL responses
against encoded foreign epitope and that the responses may be recalled many months after immunization.
We show that simultaneous disease-protective CTL responses restricted through a diversity of MHC class I
haplotypes are elicited by recombinant (r) HBsAg DNA containing multiple viral epitopes appended as a C′-
terminal polyepitope or encoded individually within the HBsAg polypeptide. CTL responses delivered by
rHBsAg DNA were elicited in the presence of HBsAg-directed antibody. These studies vindicate the use of
HBsAg as a powerful vector to deliver CTL responses to foreign antigen and have implications for a
multidisease vaccine applicable to an MHC-polymorphic population.
© 2009 Elsevier Inc. All rights reserved.Introduction
Vaccine strategies, other than attenuated or killed whole organism
vaccines, capable of safely and effectively inducing CD8+ CTL
responses in humans have not proven easy to develop (Gupta and
Siber, 1995). The small hepatitis B surface antigen (HBsAg-S), com-
prising circa 219 amino acid of the small envelope protein of hepatitis
B virus, is highly immunogenic as polypeptide (Schirmbeck et al.,
1995) and after multimerization and self-assembly into secreted
virus-like particles (VLPs; Bruss and Ganem, 1991). DNA-based HBsAg
immunization is also extremely potent at inducing CTL responses
(Schirmbeck et al., 1995; Loirat et al., 2000; Woo et al., 2006), inviting
the use of HBsAg DNA as a vector to deliver foreign antigen/epitopes
for enhanced CTL induction. The potent immunogenicity of HBsAg
DNA may be explained by prolonged or higher expression of the
HBsAg polypeptide, and biasing the response via cytokines to a Th-1
proﬁle (Leclerc et al., 1997). Importantly, the encoded HBsAg
polypeptide targets to, and accumulates in, the endoplasmic reticu-
lum as a prelude to VLP assembly (Chua et al., 2005), thereby
facilitating access to antigen processing machinery for MHC class Isearch Centre, Royal Children's
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gGuo@hotmail.com (H. Guo),
@uq.edu.au (O. Haigh),
.au (J. Kattenbelt),
(R. Tindle).
ll rights reserved.epitope loading and presentation at the cell surface (Ishioka et al.,
1999; Anderson et al., 1991). Additionally, enhanced immunogenicity
of foreign antigen encoded by recombinant (r) HBsAg DNA is likely
due to provision of T-helper epitopes within the HBsAg polypeptide.
Where VLP secretion of the rHBsAg is retained, CTL inductionmay also
be enhanced by presentation of CTL epitopes inmultimeric arrays, and
the capacity for antigen presentation of VLP-derived epitopes through
both endogenous and exogenous MHC class I pathways (Schirmbeck
et. al., 1995; Loirat et al., 2000).
Polyepitope vaccines, in which multiple CTL epitopes from a single
pathogen, or a number of different pathogens, are linked linearly, are
an attractive alternative to vaccines containing large numbers of
recombinant proteins/peptides, or where whole proteins are patho-
genic, e.g., oncoproteins (Thomson et al., 1996; Thomson et al., 1998).
Furthermore, the polyepitope strategy suggests the possibility of
simultaneous protection against multiple diseases for which CTL
epitopes are (or will be) known and which depend on a cellular
immune response for their resolution. Polyepitope vaccines however
require a delivery modality since polyepitope proteins are unstable
per se when delivered as proteins.
In the present study we further characterize HBsAg as a vector for
the induction of CTL responses. Using genetic vaccination with HBsAg
recombinant for CTL epitope(s), we demonstrate priming of CTL
responses with a single low dose immunization. We show that
responses may be recalled for many months after a single immuni-
zation. Antigen fused to HBsAg elicited enhanced CTL responses com-
pared with the same antigen not fused to HBsAg. We investigated
69D. Chen et al. / Virology 398 (2010) 68–78HBsAg DNA as a vector for the delivery of multiple CTL epitopes from
pathogens relevant in human disease, expressed either as a CTL
polyepitope extension, or as epitopes inserted individually into the
HBsAg backbone. We show that responses to the epitopes correlated
with disease protection in murine models of infectious and neoplastic
disease. We also demonstrate that the efﬁcacy of rHBsAg DNA vaccine
to elicit a CTL response to inserted foreign epitope is not diminished in
the presence of pre-existing HBsAg antibody; this is of relevance since
putative human recipients of an rHBsAg DNA vaccine may have pre-
existing HBsAg antibody, or B-cell memory, from prior hepatitis B
virus (HBV) vaccination.
These data vindicate the use of HBsAg DNA as a powerful vector for
the delivery of foreign CTL epitopes. They demonstrate that multiple
epitopes may be delivered as a polyepitope extension, or inserted
individually into the HBsAg backbone. The ﬁndings have implications
for delivery of multiple epitopes from the same, or different, patho-
gens, applicable to an MHC-polymorphic (e.g., human) population.
Results
A single low dose injection of rHBsAg DNA is sufﬁcient to prime for a
CTL response to foreign epitope
We investigated the efﬁcacy of HBsAg as a DNA vector to deliver
CTL responses to inserted foreign antigen. Conventional plasmid DNA
vaccines require circa 10–100 μg DNA, and often more than one
immunization, to prime CTL responses in mice (Kirman and Seder,
2003). This has implications for scaling up and for design of DNA
vaccines for use in humans. We therefore asked whether an rHBsAg
DNA vaccine could be used in substantially lower amounts. We used
the previously described pM215ΔGLS construct (Woo et al., 2006)
as an immunogen. Essentially it contains a single DNA insertion
encoding a 15mer amino acid CTL epitope of respiratory syncytial
virus (RSV) F protein (Table 1) replacing excised DNA encoding the
GLSPTVWLSV CTL epitope of HBsAg. Groups of mice were immunized
once with a range of amounts of pM215ΔGLS (0.1–100 μg). To
investigate effector responses we quantiﬁed by ELISPOT assay the
number of cells producing epitope-speciﬁc interferon-gamma (IFN-γ)
secretion in ex vivo splenocytes. Ex vivo splenocytes from mice
immunized with doses in the range 10–100 μg, but not 0.1–1 μg, DNA
secreted IFN-γ when cultured with, but not without, cognate ESY
peptide (Fig. 1A, top panel). Although no effector response was
detected in mice immunized with 0.1 μg and 1 μg DNA, we asked
whether these mice were nevertheless primed for a response that
could be recalled with cognate antigen. Splenocytes from immunized
mice were restimulated for 6 days in vitro with ESY peptide and then
reacted in ELISPOT assay in the presence or absence of ESY peptide.Table 1
Foreign CTL epitopes included in recombinant HBsAg DNA vaccinesa.
Epitope Virus protein Restriction Reference
RAHYNIVTF Human papillomavirus
(HPV)16 E7
H-2Db Feltkamp et al. (1993)
ESYIGSINNITKQSA Respiratory syncytial virus
(hRSV) F
H-2Kd Jiang et al. (2002)
GILGFVFTKL Inﬂuenza A (Flu) matrix HLA A⁎02 Callan et al. (1995)
VGALIFTKL Human metapneumovirus
(hMPV) N
H-2Kb Herd et al. (2006)
SIINFEKL (Ovalbumin) H-2Kb Bellone et al. (2000)
KLILALLTFL Human metapneumovirus
(hMPV) SH
HLA A⁎02 Herd et al. (2006)
LLMGTLGIV Human papillomavirus
(HPV) 16 E7
HLA A⁎02 Ressing et al. (1999)
YLLEMIWRL Epstein-Barr virus
(EBV) LMP1
HLA A⁎02 Hislop et al. (2007)
a In the text, epitopes are named by the ﬁrst three amino acids (e.g., RAH denotes
RAHYNIVTF).The restimulated splenocytes secreted IFN-γ when cultured in vitro
with, but not without, ESY peptide. To extend the ﬁndings from the
ELISPOT assay, CTL responses were also measured by 51Cr release
cytotoxicity assay. Restimulated splenocytes from groups of mice
immunized with the range of doses of pM215ΔGLS speciﬁcally killed
target cells pulsed with the ESY epitope, but not unpulsed target cells
(Fig. 1A, bottom panel).
Dose-matched groups of control mice immunized with HBsAg
wild-type DNA (pHBsAg W/T) were included in the above expe-
riments. Splenocytes from groups of mice immunized with pHBsAg
W/T tested following restimulation with ESY peptide did not secrete
IFN-γ above background (i.e., the level observed when cultured with-
out peptide), nor did they kill ESY-expressing target cells (data not
shown).
These data indicate that a single, low dose (0.1 μg), immunization
with rHBsAg DNA primes for a CTL response to inserted foreign
epitope.
rHBsAg DNA vaccine primes for a durable memory response
Groups of mice were immunized once with pM215ΔGLS. We asked
whether themice were primed for a response that could be recalled at
later time points. Ex vivo effector and in vitro-restimulated CTL res-
ponses were measured by IFN-γ ELISPOT and by 51Cr release cyto-
toxicity assay, at deﬁned time points up to 4 months post-
immunization. The ex vivo effector response declined by 1 month
and was not detectable at 2 months following immunization (Fig. 1B,
top panel). We asked whether the mice were nevertheless primed for
a response that could be recalled at later time points. Splenocytes
from immunized mice were restimulated in vitro with ESY peptide
and then reacted in ELISPOT assay in the presence or absence of ESY
peptide. Restimulated splenocytes harvested from mice up to 4
months after immunization (latest time point examined) secreted
IFN-γ when cultured in vitro with, but not without, ESY peptide
(Fig. 1B, middle panel). We also measured CTL responses in spe-
ciﬁcally restimulated splenocytes by 51Cr release cytotoxicity assay.
Restimulated splenocytes harvested from mice up to 4 months after
immunization with pM215ΔGLS speciﬁcally killed target cells pulsed
with the ESY epitope, but not unpulsed target cells (Fig. 1B, bottom
panel). While the CTL responses were still substantial at 4 months,
there was a trend to decline over the 4-month period (Fig. 1B, middle
and bottom panels).
Together, these data indicate that a single immunization with
rHBsAg DNA vaccine primes for a memory response, which can be
recalled at least up to 4 months after immunization.
Immunization with rHBsAg DNA expressing foreign epitopes as a
C′ terminal polyepitope extension elicits multiple CTL responses
We probed the ability of rHBsAg DNA vector to deliver multiple
foreign CTL epitopes. We deliberately selected epitopes of varying
immunodominance involved in CTL-mediated protection in mouse
models of a number of human diseases (Table 1). In a ﬁrst series of
experiments we investigated the capacity of the HBsAg gene ex-
tended at the 3′ prime end with a minigene encoding a linear
polyepitope comprising eight foreign CTL epitopes (pHBsAg-Poly-
epitope#3, Fig. 2A). Mice received a single immunization with
pHBsAg-Polyepitope#3 or pHBsAg W/T. Effector CTL responses were
subsequently quantiﬁed in ex vivo splenocytes by epitope-speciﬁc
IFN-γ secretion. A signiﬁcantly higher number of splenocytes from
mice immunized with pHBsAg-Polyepitope#3 secreted IFN-γ when
cultured in vitro with peptides RAH, ESY and SII (Table 1) than
without peptide (Fig. 3A). Ex vivo splenocytes from mice immunized
with pHBsAg W/T cultured in vitro with these peptides did not
secrete IFN-γ above the level observed when cultured without
peptide (Fig. 3A).
Fig. 1. Dose requirements for CTL response to rHBsAg DNA immunogen and longevity of response. (A) Groups of mice were immunized once intradermally with a range (0.1–100 μg)
of doses of pM215ΔGLS. IFN-γ-secreting splenocytes harvested 2 weeks later were quantiﬁed by ELISPOT assay either ex vivo (top panel) or after 6 days restimulation in vitro with
ESY peptide (middle panel). Splenocytes were incubated for 15– 18 h with or without ESY peptide as indicated. (Bottom panel) Groups of mice were immunized as above. Percent
cytotoxicity of splenocytes restimulated with ESY peptide wasmeasured in a 51Cr release assay using P815 target cells pulsed with or without ESY peptide as indicated. (B)Mice were
immunized once with 100 μg pM215ΔGLS. Splenocytes from groups of three mice were harvested at intervals of 4 months, and IFN-γ-secreting splenocytes quantiﬁed either ex vivo
(top panel) or after restimulation (middle panel) as described above. (Bottom panel) Percent cytotoxicity of splenocytes restimulated with ESY peptide was measured in a 51Cr
release assay as described above. Bars represent means±S.D. of six (ELISPOT assay) or three (51Cr release assay) replicates.
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epitope#3 would prime CTL capable of restimulation and of killing
target cells displaying the encoded foreign epitopes. Splenocytes from
pHBsAg-Polyepitope#3-immunizedmicewere restimulated for 6 days
in vitro with each of the encoded foreign epitopes individually, and
then reacted in ELISPOT assay. Signiﬁcantly higher numbers of
restimulated splenocytes from pHBsAg-Polyepitope#3-immunized
mice secreted IFN-γ when cultured in vitro with peptides RAH, GIL,
and SII thanwithout peptide (Fig. 3B). The numbers of IFN-γ-secreting
cells per 106 splenocytes were signiﬁcantly higher (4–15 fold) in these
restimulated splenocytes than in ex vivo splenocytes indicating that
cognate restimulation had occurred. Splenocytes restimulated with
these epitopes, and those restimulated with epitopes ESY or VGA
speciﬁcally killed cognate epitope-pulsed, but not unpulsed, target
cells (Fig. 3C). Restimulated splenocytes from pHBsAg W/T-immu-
nized mice did not secrete levels of IFN-γ above background, orspeciﬁcally kill peptide-pulsed target cells (Figs. 3B and C). The results
from mice immunized with pHBsAg-Polyepitope#3 were comparable
to those obtained from mice immunized with a large molar excess of
individual epitope peptides in adjuvant (Figs. 3 B and C).
We were concerned that although the above immunization
regimen elicited responses to ﬁve of the eight foreign epitopes
encoded by pHBsAg-Polyepitope#3, no responses were recorded to
subdominant epitopes KLI, LLM and YLL. To address this, we adopted a
prime-boost approach for the “weakest” of these epitopes (LLM).Mice
immunized once with pHBsAg-Polyepitope#3 were boosted by a later
immunization with a low dose of LLM peptide, and the CTL response
subsequently evaluated. Restimulated splenocytes from these mice,
but not mice immunized with pHBsAg-Polyepitope#3 without
peptide boost, or mice immunized with peptide without prior
pHBsAg-Polyepitope#3 prime, speciﬁcally killed target cells expres-
sing the LLM epitope (Fig. 3D).
Fig. 2. Schematics of rHBsAg DNA vaccines encoding multiple foreign CTL epitopes. (A)
pHBsAg-Polyepitope#3. DNA encoding eight foreign CTL epitopes (denoted by ﬁrst
three amino acids of sequence; single letter code) was appended to the 3′ prime end
of a codon optimized HBsAg minigene in a mammalian expression vector. The epi-
topes were restricted through murine (H-2b, H-2d) and human (HLA-A2) MHC class I
alleles. Epitopes were separated by “spacer” sequences. (B) rHBsAg-multiepitope#2.
Six DNA minigenes encoding CTL epitopes were inserted at various sites into
DNA encoding HBsAg to replace endogenous HBsAg CTL epitopes, as described (Haigh
et al., 2007).
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rHBsAg plasmid DNA encoding a polyepitope appended at the C′
terminus primes for IFN-γ-secreting effector or restimulated T-cell
responses, and for cytotoxic responses. These responses were
recorded outright for “strong” CTL epitopes, and after subsequent
boosting for (at least one of) the “weak” CTL epitopes.
Immunization with pHBsAg-Polyepitope#3 elicits signiﬁcantly higher
CTL responses than immunization with pPolyepitope#3
We compared CTL responses induced following immunization
with plasmid DNA encoding polyepitope#3 fused with HBsAg andplasmid DNA encoding polyepitope #3 alone. Groups of mice
received a single immunization of pHBsAg-Polyepitope#3 or pPolye-
pitope#3. The latter is identical to pHBsAg-Polyepitope #3, but
without the HBsAg component. Speciﬁc effector CTL responses to two
epitopes in polyepitope#3 (RAH and SII, Table 1) were subsequently
quantiﬁed in ex vivo splenocytes by IFN-γ secretion. A signiﬁcantly
higher number of splenocytes from mice immunized with pHBsAg-
Polyepitope#3 than with pPolyepitope#3 secreted IFN-γ when
cultured in vitro with peptide RAH or SII. This was the case when the
respective immunogens were compared at high (50 μg; ⁎pb0.0001,
⁎⁎pb0.0001) and low (5 μg; ⁎⁎⁎pb0.003, ⁎⁎⁎⁎pb0.05) immunization
doses (Fig. 4).
These data demonstrate that delivery of a plasmid DNA immuno-
gen encoding a polyepitope fused with HBsAg elicits higher numbers
of effector IFN-γ-secreting CTL than plasmid DNA encoding the same
polyepitope alone (i.e., not fused to HBsAg).
Immunization with rHBsAg DNA expressing foreign epitopes inserted
into HBsAg backbone elicits multiple CTL responses
In a further series of experiments, we examined whether an
rHBsAg vaccine encoding multiple epitopes inserted individually
into the HBsAg backbone (pHBsAg-Multiepitope #2) would elicit
multiple CTL responses. The essential features of pHBsAg-Multi-
epitope #2 are shown in Fig. 2B. DNA fragments encoding six CTL
epitopes (Table 1) were inserted at six separate locations within the
HBsAg minigene, to replace DNA encoding six HBsAg CTL epitopes
that we deleted from these locations. We examined the efﬁcacy of
induction of IFN-γ-secreting and speciﬁc cytotoxic responses in mice
immunized with pHBsAg-Multiepitope #2. Splenocytes from mice
immunized with HBsAg-Multiepitope#2 or pHBsAg W/T were
restimulated for 6 days in vitro with each of the six encoded foreign
epitopes and reacted in ELISPOT assay. Signiﬁcantly more spleno-
cytes from mice immunized with pHBsAg-Multiepitope#2 secreted
IFN-γ when cultured in vitro with, than without, peptides GIL, ESY,
RAH, and KLI (Fig. 5A). In addition, restimulated splenocytes from
three of these epitopes speciﬁcally killed cognate epitope-pulsed,
but not unpulsed, target cells (Fig. 5B). Restimulated splenocytes
from pHBsAg W/T-immunized mice did not secrete levels of IFN-γ
above background, or speciﬁcally kill peptide-pulsed target cells
(Figs. 5A and B).
These data indicate that CTL responses to foreign epitopes may
be elicited by an rHBsAg DNA vaccine encoding multiple foreign
CTL epitopes inserted singly at individual locations in the HBsAg
backbone.
Immunization with rHBsAg DNA expressing multiple CTL epitopes
conveys tumor protection
We investigated the tumor protective efﬁcacy of rHBsAg DNA
expressing multiple epitopes. Groups of mice were immunized with
pHBsAg-Polyepitope#3 or with pHBsAg-Multiepitope#2.1. We ﬁrst
conﬁrmed in two representative mice per group that immunization
evoked an IFN-γ-secreting effector immune response directed to the
RAH epitope of the tumor-associated antigen HPV 16 E7, as per Figs. 3
and 5 (data not shown). The remaining mice were challenged with
E7-expressing TC-1 tumor. To ensure a stringent test of protection, we
used a tumor challenge dose (2×105 per mouse) four times higher
than the previously determined minimal dose (5×104 per mouse),
which produces tumor growth in 100% of unimmunized mice. We
used the appropriate log rank statistic to compare survival distribu-
tions (i.e., time to incidence of tumor). No mice in the pHBsAg-
Multiepitope#2 immunized group acquired tumors (Fig. 6A). In
contrast, all mice in the group immunized with pHBsAgW/T acquired
tumors by day 10. In the group immunized with pHBsAg-Polyepi-
tope#3, fewer mice acquired tumors, and at later time points after
Fig. 3. Immunization with pHBsAg-Polyepitope#3 elicits cognate epitope speciﬁc IFN-γ-secreting and cytotoxic T-cell responses. Groups of A2Kb or Balb/c mice (as appropriate to
MHC restriction; three per group) were immunized once id. with 50 μg pHBsAg-Polyepitope#3 or with 50 μg pHBsAg (W/T) or with peptide+adjuvant. IFN-γ-secreting splenocytes
harvested 14 days (DNA immunizations) or 10 days (peptide immunizations) later were quantiﬁed by ELISPOT assay either (A) ex vivo or (B) after 6 days restimulation in vitrowith
individual cognate peptides as indicated. (C) Percent cytotoxicity of restimulated splenocytes wasmeasured in a 51Cr release assay using EL4.A2 (H-2b and HLA A⁎02) or P815 (H-2d)
target cells as appropriate pulsed with or without cognate peptide as indicated. (D) Immunization with pHBsAg-Polyepitope#3 primes for a CTL response to epitope LLM, which can
be boosted with peptide immunization. Two groups of A2Kb mice (three mice per group) were immunized once with 100 μg id. of pHBsAg-Polyepitope#3. Fourteen days later, the
groups were boosted with 5 μg LLM peptide plus adjuvant, or adjuvant alone. A third group received 5 μg LLM peptide plus adjuvant, without prior priming with pHBsAg-
Polyepitope#3. Splenocytes harvested 8 days later were restimulated with LLM peptide in vitro for 6 days, then reacted with EL4.A2 target cells pulsed or not pulsed with LLM
peptide in a 51Cr release cytotoxicity assay. Bars represent means±S.D. of six (ELISPOT assay) or three (51Cr release assay) replicates.
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(Fig. 6A). Additionally, individual TC-1 tumor growth was signiﬁcant-
ly slower in the pHBsAg-Polyepitope#3-immunized mice that
developed tumors compared with the pHBsAg W/T-immunized
mice (pb0.008 Fig. 6B).
We also asked whether immunization with pHBsAg-Polyepi-
tope#3 would protect against B16.OVA tumor, which expresses the
SII CTL epitope. Tumor onset was signiﬁcantly slowed (p=0.011)
compared to B16.OVA-challenged mice immunized with rHBsAgW/T, although only 20% of mice remained tumor free (Fig. 6C).
Individual B16.OVA tumor growth was signiﬁcantly slower in the
pHBsAg-Polyepitope#3-immunized mice that developed tumors
compared with the pHBsAg W/T-immunized mice (p=0.05,
Fig. 6D).
These data indicate that immunization with an rHBsAg DNA
encoding tumor-associated epitopes among other foreign epitopes
confers a degree of tumor protection, associated with epitope-speciﬁc
IFN-γ-secreting CTL responses.
Fig. 4. Immunization with plasmid DNA encoding Polyepitope#3 fused with HBsAg
elicits signiﬁcantly higher IFN-γ-secreting responses than immunization with plasmid
DNA encoding Polyepitope#3 alone. Groups of A2Kb mice were immunized once id.
with 5 μg or 50 μg pHBsAg-Polyepitope#3 or pPolyepitope#3. IFN-γ-secreting
splenocytes harvested 24 days later were quantiﬁed by ex vivo ELISPOT assay with
and without peptide. Bars represent means±S.D. of six replicates. Background spot
counts obtained in the absence of peptide have been subtracted.
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pulmonary hRSV infection
We investigated whether immunization of mice with pHBsAg-
Polyepitope#3 (which expresses an hRSV CTL epitope; ESY, Table 1)
would confer some protection against pulmonary infection in mice
challenged with hRSV. Groups of H-2d mice were immunized twice
with 100 μg pHBsAg-Polyepitope#3 or pHBsAg W/T. We ﬁrst
conﬁrmed in two representative mice per group that immunization
with pHBsAg-Polyepitope#3 evoked an IFN-γ-secreting effector
immune response directed to ESY as in Fig. 3 (data not shown). The
remaining mice were inoculated intranasally (in.) with hRSV, and 4
days later, lungs were removed for virus quantiﬁcation. The mean
hRSV titer was signiﬁcantly reduced in the group immunized with
pHBsAg-Polyepitope#3, compared with the group immunized with
pHBsAg W/T (Fig. 7).
Immunization with rHBsAg DNA vaccine elicits a CTL response in the
presence of an HBsAg antibody response
Putative human recipients of rHBsAg vaccines may be primed for
an HBsAg-directed B-cell mediated antibody response as a result of
prior vaccination with HBV vaccine (comprised of W/T HBsAg VLPs).
It is thus relevant to ask whether prior B-cell immunity might impair
the efﬁcacy of subsequent rHBsAg DNA vaccination intended for CTL
induction. To address this we induced an HBsAg antibody response in
mice, and then immunized with rHBsAg DNA to induce a CTL
response. Groups of mice were immunized twice with HBV vaccine
(Engerix-B, GlaxoSmithKline) or saline. Two weeks later, HBsAg
antibody titer was determined by ELISA assay, and mice were
immunized once with pM215ΔGLS. To investigate effector responses
we quantiﬁed epitope-speciﬁc IFN-γ secretion of ex vivo splenocytes
by ELISPOT assay. Ex vivo splenocytes from mice that displayed
substantial HBsAg serum antibody titers secreted IFN-γ when
cultured with, but not without, cognate ESY peptide (Fig. 8A). The
numbers of splenocytes secreting IFN-γ in responses to ESY peptide
did not differ signiﬁcantly from those of mice that had no HBsAg
serum antibody at the time of pM215ΔGLS immunization (Fig. 8B).We
also measured CTL responses in speciﬁcally restimulated splenocytes
by 51Cr release cytotoxicity assay. Restimulated splenocytes from
mice with pre-existing HBsAg serum antibody killed target cells
pulsed with cognate ESY epitope as effectively as splenocytes from
mice without pre-existing HBsAg serum antibody (Fig. 8C).These data indicate that the ability to mount immunization-
induced CTL responses to rHBsAg DNA encoded antigens are not
compromised by the presence of circulating HBsAg antibody at the
time of DNA vaccination.
Discussion
We (Woo et al., 2006), and others (Berkower et al., 2004; Bisht et
al., 2002), have previously suggested that the potent immunogenicity
of HBsAg may be exploited to deliver foreign antigens for CTL
induction. Here we demonstrate that a single immunization at low
dose is sufﬁcient to prime for CTL responses against encoded foreign
epitope.We demonstrate that the response to foreign CTL epitopewas
long lived (i.e., N4 months). We show that polyepitope antigen fused
to HBsAg elicited enhanced CTL responses comparedwith polyepitope
not fused to HBsAg. We demonstrate that immunization with rHBsAg
DNA encoding multiple human disease-relevant foreign epitopes,
expressed either as a C′ terminal polyepitope extension or encoded
within the HBsAg polypeptide backbone, elicits multiple CTL
responses restricted through four MHC class I haplotypes, which
afforded a measure of disease protection (where tested). Further, we
show that CTL responses delivered by rHBsA DNA were elicited in the
presence of HBsAg-directed antibody.
Studies examining delivery of HBsAg (W/T) as a DNA vaccine
comparedwith delivery as a VLP vaccine suggest that the former is the
preferred modality for the induction of CTL-mediated immunity in
terms of immunogenic efﬁcacy, as well as economically and
practically (Davis et al., 1996). Continuous exposure to small doses
of antigen (Leclerc et al., 1997) produced by on-going transcription
from persisting HBsAg DNA (e.g., in muscle cells (Leclerc et al., 1997)
and follicular dendritic cells (Gray et al., 1991)) is likely responsible
for the persistence of effector andmemory CTL responses (Davis et al.,
1995, 1996).
In construction of both pHBsAg-Polyepitope#3 and pHBsAg-
Multiepitope#2 we invoked measures designed to help preserve
tertiary structure of the rHBsAg molecules. However, neither cons-
truct readily formed VLPs when transfected into mammalian (Huh)
cells (data not shown). This underscores the relative lack of pre-
dictability of VLP-forming propensity by HBsAg engineered to contain
foreign sequences (Bruss and Ganem, 1991; Bryder et al., 1999;
Michel et al., 2007). Early data suggested that CD8+ive CTL induction
by intracellularly translated HBsAg protein occurs through the
“classical” endogenous pathway and also through the “alternative”
exogenous pathway via secreted HBsAg particles or protein taken up
by antigen presenting cells (Schirmbeck et al., 1994). More recent
data, however, indicate that neither HBsAg particle formation, nor its
secretion or liberation, plays a signiﬁcant role in the development of
the powerful cytotoxic immune responses, which occur following
HBsAg DNA vaccination (Sbai et al., 2002). Our ﬁndings are congruent
with this latter view.
The indifferent immunogenicity of subdominant epitopes in the
presence of one or more immunodominant epitopes can, in some
circumstances, compromise the efﬁcacy of vaccines encoding
multiple CTL epitopes (even among epitopes restricted through
different MHC class I molecules (Schirmbeck et al., 1994)).While
polyepitope DNA vaccines designed to encode only immunodomi-
nant epitopes elicit responses to all epitopes (Thomson et al., 1998),
in the present study we deliberately elected to include epitopes of
varying degrees of immunodominance since this is more likely to
reﬂect the real situation among epitopes protective for diseases for
which vaccines are required. Among the epitopes that we have
chosen, RAH, ESY, SII and GIL may be regarded as being at the
“strong” end of the spectrum of immunodominance, while epitopes
VGA, KLI, YLL and LLM are at the “weak” end (references in Table 1
and our unpublished observations). Notably, in mice immunized
with pHBsAg-Polyepitope#3 or with pHBsAg-Multiepitope#2, the
Fig. 5. Immunization with rHBsAg-Multiepitope#2 elicits cognate epitope-speciﬁc IFN-γ-secreting and cytotoxic T-cell responses. Groups of A2Kb or Balb/c mice (as appropriate to
MHC class I restriction; three per group) were immunized once id. with 50 μg rHBsAg-Multiepitope#2 or with 50 μg pHBsAg (W/T) or with peptide+adjuvant. Splenocytes
harvested 14 days (DNA immunizations) or 10 days (peptide immunizations) after last immunization were restimulated in vitrowith cognate peptide for 6 days, then (A) reacted in
IFN-γ ELISPOT with or without peptide or (B) reacted in 51Cr release cytotoxicity assay with peptide-pulsed or unpulsed EL4.A2 (H-2b and HLA A⁎02) or P815 (H-2d) target cells as
appropriate. Bars represent means±S.D. of six (ELISPOT assay) or three (51Cr release assay) replicates.
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dominant” epitopes (Fig. 3), though the mice were clearly primed to
several of the “less immunodominant” epitopes (Figs. 3C, D and 5A).
These data suggest that while the immunization primed for CTL
responses to most, if not all, encoded foreign epitopes, the immuno-
dominance of individual epitopes was not changed by vectoring with
HBsAg.The observation that CTL-mediated disease resolution is usually
focused on one or a few epitopes (Rosenberg 2001), and that a
majority of MHC class I polymorphism is contained within relatively
few epitope cross-presenting class I “supertypes” (at least in humans;
Sidney et al., 2008), suggests that, in principle, wide population
coverage against a number of diseases may be feasible with rHBsAg
vaccines containing a limited number of CTL epitopes. While animal
Fig. 6. Immunization with rHBsAg DNA encoding multiple CTL epitopes confers some tumor protection. H-2b mice (seven per group) were immunized twice id. 14 days apart with
50 μg pHBsAg-Polyepitope#3, with pHBsAg-Multiepitope#2.1 or with pHBsAg W/T. Induction of RAH (HPV E7 epitope)- and SII (OVA epitope)-speciﬁc IFN-γ-secreting
splenocytes was conﬁrmed in two representative mice per group by ex vivo ELISPOT 14 days after the second immunization (not shown). The remaining ﬁve mice per group were
then immediately challenged with (A, B) 2×105 TC-1 tumor cells, or (C, D) 105 B16-OVA melanoma cells sc. on the ﬂank. Tumor growth was monitored for 42 days as the
percentage of mice with palpable tumor, and by calliper measurement of tumor size. Mice with tumors in excess of 1000 mm3 were euthanized in accordance with animal ethics
requirements. Results are expressed (A, C) as tumor-free mice (%) at the indicated time points and (B, D) as tumor volume in mice with time. In (B) and (D), closed symbols denote
individual mice immunized with pHBsAg-W/T; open symbols denote individual mice immunized with pHBsAg-Polyepitope#3.
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diseases simultaneously, our data are consistent with the notion of
simultaneous protection afforded by CTL against multiple antigens.
Equally, the strategy of HBsAg-vectored delivery may be applied to
multiple epitopes from the same pathogen (e.g., HIV (Michel et al.,
2007)) or group of related pathogens, e.g., respiratory viruses RSV and
hMPV (unpublished observations). We demonstrate that memory
responses, measured in vitro, are long-lived (Fig. 1). In experiments
using HBsAg multiepitope vaccines containing one or multiple
insertions of the RAH tumor epitope (i.e., very similar to Multi-
epitope#3 described in this study), we have shown that mice were
totally protected against the TC-1 tumor 100 days after vaccination,
using a tumor dose that gave 100% tumor incidence in unvaccinated
mice (Haigh et al., 2007).Fig. 7. Immunization with pHBsAg-Polyepitope#3 reduces hRSV viral load in lungs.
H-2d mice (seven per group) were immunized twice id. with pHBsAg-Polyepitope#3 or
with pHBsAg W/T at an interval of 10 days. Induction of hRSV epitope (ESY)-speciﬁc
IFN-γ-secreting splenocytes was conﬁrmed by ELISPOT 14 days later from two
representative mice per group (not shown). The remaining ﬁve mice per group were
challenged in. with 8×105 pfu hRSV. hRSV in the lungs was quantiﬁed 4 days later by
plaque assay. Results are expressed as mean viral titer per lung per group±S.D.Generally, while CTL-inducing vaccines will not protect against
viral pathogen primary infection, they will protect against spread of
de novo infection from, and disease caused by, infected host cells (or
tumor-antigen bearing neoplastic cells). Thus, vaccine-induced
speciﬁc CTL memory laid down before primary infection (or cell
transformation) is likely to confer a prophylactic aswell as therapeutic
beneﬁt against pathogen- or transformation-induced disease. Immu-
nizationwith the one of the rHBsAg vaccines gave complete protection
against tumor challenge (Fig. 6). Protection against RSV challenge,
though statistically signiﬁcant, was less convincing. However, limited
protection against RSV challenge has also been the experience of
workers using CTL-eliciting ESY chimeric-peptide-based vaccines
(Hsu et al., 1998). The limited reduction in RSV titer may be because
the frequency or avidity of CTLswas not sufﬁcient for viral clearance in
vivo (Alexander-Miller et al., 1996); only adoptive transfer of high
doses of RSV-speciﬁc CTLs seems to clear virus in this model (Cannon
et al 1988).
Other studies from our laboratory show that immunization with
rHBsAg induces CTL responses not only to foreign protein insert but
also to HBsAg CTL epitopes within the vector backbone (unpublished
data). rHBsAg DNA vaccines thus have the potential to protect against
on-going HBV infection.
A direct side-by-side comparison of the efﬁcacy of C′ terminal
extension with CTL polyepitope (i.e., pHBsAg-Polyepitope#3) versus
insertion of individual epitopes into the backbone (i.e., pHBsAg-
Multiepitope#2) was not made. It is debatable whether generically
applicable conclusions can be drawn from comparing speciﬁc poly-
epitope and multiepitope vaccines since the strength of response to
a particular epitope common to each will vary depending upon a
number of (non-independent) variables, e.g., location of the epitope
within the HBsAg backbone or within the polytope, the proximity of
other more immunodominant epitopes, and proteosomal cleavage
Fig. 8. Pre-existing HBsAg antibody does not reduce epitope-speciﬁc IFN-γ secretion or cytotoxic efﬁcacy of splenocytes from mice immunized with rHBsAg DNA. (A) Groups of
H-2d mice (three per group) were immunized twice at an interval of 2 weeks with 4 μg of Engerix B vaccine sc., or with saline, and HBsAg serum antibody was measured 2 weeks
later by ELISA assay. (B) Engerix B- and saline-treated mice were immunized immediately after ELISA assay with 100 μg pM2 15ΔGLS. IFN-γ-secreting splenocytes harvested 14
days later were quantiﬁed ex vivo by ELISPOT in the presence or absence of ESY peptide. (C) Ex vivo splenocytes were restimulated for 6 days in vitro and speciﬁc cytotoxicity
was measured in 51Cr release assay using P815 (H-2d) target cells pulsed with ESY peptide or unpulsed. Bars represent means±S.D. of six (ELISPOT assay) or three (51Cr release
assay) replicates.
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strategies, both are effective for induction of CTL responses to inserted
epitopes. C′ terminal extension is logistically preferable as vaccines
using this rHBsAg strategy are more easily engineered. We have not
examined potential limitations on the number of epitopes that can be
delivered as a polytope extension, but it is likely to exceed the number
that can be delivered by epitope insertion into the HBsAg backbone
using our strategy of substituting HBsAg CTL epitopes with foreign
epitopes. Constraints on size of foreign polyepitope insert are likely to
be less critical for derivation and application of rHBsAg DNA vaccines
than rHBsAg VLP vaccines.
While a number of clinical trials have shown that the magnitude
of immune responses primed by standard DNA vaccines is generally
weaker in humans (and non-human primates) than in small
mammals, recent strategies (e.g., particularly those targeting immu-
nogens to the endoplasmic reticulum) are beginning to overcome
this (Rice et al., 2008). A major difﬁculty has hitherto been the
prohibitive scaling up of the immunogenic DNA dose from mouse to
primate. Our observation therefore that rHBsAg-based DNA vaccina-
tion primes for a response, and can be recalled, using low doses
(Fig. 1) suggests that HBsAg-vectored delivery might offer a solution
to this difﬁculty. This view receives support from immunization trials
in humans in which HBsAg (W/T) DNA vaccines required a dose up
to 2500-fold lower than used in previous clinical trials with
conventional DNA (Roy et al., 2000). Furthermore, the magnitude
of responses obtained in trials of HBsAg DNA in humans (Roberts
et al., 2005) appears similar to that which we and others have
obtained in mice.
In this study we demonstrate that recombinant HBsAg DNA
vaccines encoding multiple CTL epitopes delivered as a polyepitope or
inserted individually into the HBsAg backbone elicits concomitant
responses to a number of pathogens and tumors restricted through a
diversity of MHC class I haplotypes. We show that rHBsAg DNA
vaccine elicits concomitant partial protection against neoplastic and
infectious disease. Plasmid DNA encoding polyepitope antigen fused
to HBsAg elicited enhanced CTL responses comparedwith polyepitope
not fused to HBsAg. Further, we show that CTL responses delivered
by rHBsAg DNA were elicited in the presence of HBsAg-directed
antibody. These results suggest the applicability of HBsAg as a
vector in humans to simultaneously deliver multiple disease-relevant
foreign CTL responses applicable to an MHC outbred population,
including those who may have been primed to HBsAg by HBV
vaccination.Materials and methods
pHBsAg-Polyepitope#3
The hepatitis B surface antigen codon sequence of Valenzuela et al.
(1979) was used as a basis for the codon optimization of the gene using
codons described by Cid-Arregui et al. (2003). Essentially, oligonucleo-
tides were synthesized as 80mers (Geneworks, Australia), which
covered the full-length sequence of the HBsAg in the 5′ to 3′ direction.
A series of CTL epitopes was interspersed with spacer regions
comprising the sequences HWSISKPQ, RAKT, RADT, RDTA or RTKA
(Michel et al., 2007) to reduce the overall hydrophobicity of the
polyepitope (Fig. 2A). Spacer sequence HWSISKPQ is mimotope of an
hRSV F-protein B-cell epitope (Chargelegue et al., 1998). A set of
complementary oligonucleotides was also synthesized, which over-
lapped the termini of the forward oligonucleotides by 40 bases. Each
oligonucleotide was then added to a PCR reaction at a concentration of
5 ng/μl in the presence of PrimeSTAR HS DNA polymerase (Takara Bio,
Shiga, Japan). PCR reaction conditions were as described by the
manufacturer. The PCR product was puriﬁed from a 1% agarose gel after
electrophoresis using UltraClean GelSpin cartridges (Mo Bio Labs,
California) according to the manufacturer's instructions and then
incubated in the presence of dNTPs ( 10mM) and Taq DNA polymerase
(Promega, USA) for the addition of 3′-terminal adenosine residues. The
DNA was ligated into pGEM-T easy vector (Promega, USA) using
T4DNA ligase (Promega, USA) according to the manufacturer's instruc-
tions. The DNA insert into the pGEM-T easy plasmid was sequenced in
both directions and any errors in the sequence corrected using the
QuickChange II site-directed mutagenesis kit (Stratagene, Texas, USA).
To minimize internal initiation of truncated proteins, we prefer-
entially selected epitopeswithoutmethionine residues, and those two
epitopes (LLM and YLL) that did contain a methionine residue were
included at the extreme C′ terminus. The construct was designed to
include an arginine residue at the C′ terminus of each epitope, in order
to maximize antigen processing and immunogenicity (Livingston et
al., 2001). We also elected to exclude epitopes containing cysteine
residues, thereby minimizing perturbation in secondary structure due
to disulﬁde bonding.
pPolyepitope#3
The CTL polyepitope was ampliﬁed from the HBsAg-Polyepitope#3
clone using the primers 5′CTGAATTCAAGCTTATGAAGCACCATCA-
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TCTGAAGGTCACGATGTTGTAGTGGGCTCTCATCTGGTGATGATGGT-
GATGGTGCTTCATAAGCTTGAATTC and cloned into the pGEMT
“Easy” vector. The HIS-6 tagged polyepitope DNA fragment was ex-
cised by EcoR1 digestion and subcloned into the pcDNA3 vector at
the EcoR1 site. The construct was veriﬁed by nucleotide sequence
analysis.
pHBsAg-Multiepitope#2
pHBsAg-Multiepitope #2 was derived essentially as described
(Haigh et al., 2007). In summary, the plasmid pcD3-HBsAgS (ayw sub-
type; Netter et al., 2001) was engineered to delete the HBsAg-speciﬁc
CTL epitopes (13VLQAGFFL21, 28IPQSLDSWWTSL39, 41FLGGTPVCL49,
97LLDYQGMLP105, 184GLSPTVWLS193 and 206SILSPFIPLL215; Ando et al.,
1993; Loirat et al., 2000) and to introduce the restriction enzyme
sites BsiW1, NheI, BspE1, Aﬂ1, BlpI and SacII respectively, by PCR-
driven site-directed mutagenesis. Synthetic oligonucleotides en-
coding the selected foreign epitopes were inserted into HBsAg
through systematic subcloning into these restriction sites to create
the construct depicted in Fig. 2B. Due to reading frame shifts
caused by addition of restriction sites, codons for alanine and
leucine (AA or A and AL) were included in the insert sequences at
the 5′ and 3′ ends of the inserted epitope oligomers. Sequences of
constructs were veriﬁed via Terminator Sequencing (ABI) Big Dye
3.1. pHBsAg-Multiepitope#2.1 is a variant of pHBsAg-Multiepitope
#2, which encodes RAH from the ﬁfth instead of the third insertion
location.
Mice
Female Balb/c (H-2d) and A2.1Kb transgenic mice (Vitiello et al.,
1991) were housed under speciﬁc pathogen-free conditions and
used at 7– 15 weeks of age. Experiments were conducted in
accordance with institutional animal ethics guidelines. A2.1Kb mice
make CTL responses restricted through both HLA A2 and H-2b class 1
molecules.
Immunization of mice and restimulation of splenocytes
Mice were immunized intradermally (id.) in the ear with puriﬁed
plasmid DNA in 50 μl saline, prepared by EndoFree Plasmid Giga Kit
(Qiagen, Australia). At pre-determined times after immunization,
spleens were removed and splenocytes were restimulated in vitro for
6 days as described (Doan et al., 1998) with 1 μg/ml cognate peptide.
For peptide immunizations, mice were immunized subcutaneously
(sc.) at the tail base with 50 μg peptide in 100 μl saline, 0.25 μg tetanus
toxoid (TT) as a source of T-helper epitopes and 10 μg Quil A adjuvant
(Le et al., 2001). Ten days later spleens were harvested and spleno-
cytes were restimulated as above.
Cells
EL4.A2 cells (Doan et al., 1998) are susceptible to speciﬁc CTL lysis
through both H-2b and HLA A⁎0201 restriction pathways. P815 is
susceptible to speciﬁc CTL lysis through the H-2d restriction pathway.
Cells were maintained as described (Doan et al., 1998).
IFN-γ ELISPOT assay
Epitope-speciﬁc gamma interferon (IFN-γ) secreting spleen cells
were enumerated ex vivo, or after restimulation, by an enzyme-linked
immunospot (ELISPOT) assay with minimal CD8+ T-cell epitope
peptides, essentially as described (Le et al., 2001). IFN-γ spots were
counted using an AID ELISPOT reader system. Results were calculated
as IFN-γ positive cells/106 spleen cells.51Cr-release CTL assay
CTL assays were conducted as previously described (Doan et al.,
1998). In summary, target cells (104 per well) sensitized at 37 °C for
1 h with 1 μg/ml cognate or irrelevant peptide, or medium alone,
and labeled with 100 μCi 51Chromium (Cr) were incubated with
effector cells at various effector-to-target cell ratios in triplicate in
96-well microtiter plates. Negative controls included wells contain-
ing target cells but no effector cells (=“background”). Supernatants
were harvested from CTL assays at 4 h, and 51Cr release was
quantiﬁed by gamma counting. Results are expressed as percent
cytotoxicity±standard deviation (51Cr release in experimental wells
minus no effector background/detergent-mediated total release
minus no effector background)×100%. Cytotoxicity values in the
absence of cognate peptide never exceeded 20% and were subtracted
from cytotoxicity values obtained in the presence of cognate
peptide.
Tumor protection assays
Groups of H-2b mice (seven per group) were immunized twice
with 100 μg pHBsAg-Polyepitope#3, with pHBsAg-Multiepitope#2 or
with pHBsAg W/T id. CTL responses to tumor epitopes RAH and SII
(Table 1) were conﬁrmed in two representative mice per group by
IFN-γ ELISPOT on ex vivo splenocytes. The following day, the
remaining ﬁve mice per group were injected sc. on the ﬂank with
2×105 TC-1 cells, which express the E7 tumor-associated antigen of
human papillomavirus type 16 (Lin et al., 1996) or with 105 B16-OVA
melanoma cells expressing ovalbumin (Bellone et al., 2000). Mice
were monitored for incidence of tumor with time to 43 days. Data are
presented as Kaplan–Meier tumor incidence curves of percent tumor-
free mice at given time points after tumor injection. Tumor volumes
were derived at intervals from calliper measurements in two
perpendicular dimensions by the formula S2 L, where S is the shorter
dimension and L is the longer dimension. Tumor volumes were
compared by Student's t-test.
Propagation of RSV and evaluation of pulmonary viral infection
hRSV A2 (VR-1302) strain (American Type Culture Collection,
Rockville, MD, USA) was propagated in HEp-2 cells essentially as
described (Graham et al., 1988) and recovered from the supernatant
following freeze/thawing of monolayers displaying a cytopathic
effect. hRSV was quantiﬁed by immunofocus assay, using goat anti-
hRSV primary antibody (Chemicon, Australia), anti-goat Ig horserad-
ish peroxidase conjugated second antibody, and tetraaminobiphenyl
hydrochloride substrate (Sigma, Australia), according to manufac-
turer's instructions. Lungs were collected 4 days after mice were
inoculated intranasally (in.) with 8×105 plaque forming units (pfu)
and RSV was quantiﬁed in lung homogenates by immunofocus assay
as described (Woo et al., 2006).
ELISA
HBsAg VLPs (Merck) were bound to Maxisorb microtiter plates
overnight at 4 °C ( 20 ng per well in PBS). Plates were blocked for
2 h at RT with 0.25% gelatin+0.1% Tween20 in PBS, prior to
addition of dilutions of test sera in wash buffer (0.125% gelatin+
0.05% Tween20 in PBS). Following incubation for 1 h at 37 °C
plates were washed and incubated with 50 μl second antibody
(anti-mouse Ig-horseradish peroxidase conjugated, Chemicon) at
1:1000 dilution, according to manufacturer's recommendation for
1 h at RT in the dark. The reaction was developed with ABTS
substrate (2, 2′-azino-di-(3-ethylbenzthiazoline sulfonic acid) and
hydrogen peroxide and read at 410 nm on a dual wavelength plate
reader.
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Experimental values were compared for signiﬁcant difference
using Student's t-test. Kaplan–Meier tumor incidence curves were
compared using the Log Rank statistic.
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